Literature DB >> 12142727

Evidence for environmental influence on CYP2D6-catalysed debrisoquine hydroxylation as demonstrated by phenotyping and genotyping of Ethiopians living in Ethiopia or in Sweden.

Eleni Aklillu1, Karin Herrlin, Lars L Gustafsson, Leif Bertilsson, Magnus Ingelman-Sundberg.   

Abstract

Black Africans show lower rates of CYP2D6- and CYP2C19-dependent drug metabolism compared to Caucasians of the same apparent genotype. To determine if environmental factors are responsible for this difference, the genotypes and phenotypes of CYP2D6 and CYP2C19 among Ethiopians living in Sweden (n = 70) were assessed and compared to our previously published data from Ethiopians living in Ethiopia (n = 114) and Swedish Caucasians (n = 134). There was no significant difference in CYP2C19 genotype or phenotype as assessed by mephenytoin between Ethiopians in Sweden or in Ethiopia. However, Swedes were significantly more rapid for CYP2C19 activity than both Ethiopian groups (P < 0.01). A comparison of the debrisoquine MR among individuals of the same CYP2D6 genotype revealed that Swedes exhibited the highest rate of debrisoquine metabolism, followed by Ethiopians in Sweden and Ethiopians in Ethiopia. The difference between the Ethiopian groups was significant (P < 0.02 using a univariate test ANOVA) and amounted to approximately 50% of the magnitude of the MR difference between Swedes and Ethiopians in Ethiopia. It is tempting to speculate that inhibitory dietary factors may explain the differences seen between the two Ethiopian groups and that these components in the past might have contributed to dietary stress-mediated selection of duplicated and multiduplicated active CYP2D6 genes, as frequently seen in Ethiopians. In conclusion, the results indicate a significant influence of environmental factors as an explanation for the difference in capacity for CYP2D6, but not CYP2C19 metabolism between Caucasians and Black Africans. Additional factors remain to be elucidated to fully explain the interethnic differences in CYP2D6 activity.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12142727     DOI: 10.1097/00008571-200207000-00005

Source DB:  PubMed          Journal:  Pharmacogenetics        ISSN: 0960-314X


  21 in total

Review 1.  The role of pharmacogenetics in nonmalignant gastrointestinal diseases.

Authors:  Michael Camilleri
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2012-02-07       Impact factor: 46.802

2.  Cytochrome P450-2D6 extensive metabolizers are more vulnerable to methamphetamine-associated neurocognitive impairment: preliminary findings.

Authors:  Mariana Cherner; Chad Bousman; Ian Everall; Daniel Barron; Scott Letendre; Florin Vaida; J Hampton Atkinson; Robert Heaton; Igor Grant
Journal:  J Int Neuropsychol Soc       Date:  2010-08-23       Impact factor: 2.892

Review 3.  Interethnic variation of CYP2C19 alleles, 'predicted' phenotypes and 'measured' metabolic phenotypes across world populations.

Authors:  I Fricke-Galindo; C Céspedes-Garro; F Rodrigues-Soares; M E G Naranjo; Á Delgado; F de Andrés; M López-López; E Peñas-Lledó; A LLerena
Journal:  Pharmacogenomics J       Date:  2015-10-27       Impact factor: 3.550

4.  Cytochrome P450 2C19 genetic polymorphisms in Ugandans.

Authors:  Jun Miura; Celestino Obua; Catherine Abbo; Sunao Kaneko; Tomonori Tateishi
Journal:  Eur J Clin Pharmacol       Date:  2008-11-11       Impact factor: 2.953

5.  CYP2D6 and CYP2C19 in Papua New Guinea: High frequency of previously uncharacterized CYP2D6 alleles and heterozygote excess.

Authors:  Nicolas von Ahsen; Mladen Tzvetkov; Harin A Karunajeewa; Servina Gomorrai; Alice Ura; Jürgen Brockmöller; Timothy M E Davis; Ivo Mueller; Kenneth F Ilett; Michael Oellerich
Journal:  Int J Mol Epidemiol Genet       Date:  2010-08-18

6.  Identification and characterization of novel sequence variations in the cytochrome P4502D6 (CYP2D6) gene in African Americans.

Authors:  A Gaedigk; A Bhathena; L Ndjountché; R E Pearce; S M Abdel-Rahman; S W Alander; L DiAnne Bradford; P K Rogan; J Steven Leeder
Journal:  Pharmacogenomics J       Date:  2005       Impact factor: 3.550

7.  High CYP2A6 enzyme activity as measured by a caffeine test and unique distribution of CYP2A6 variant alleles in Ethiopian population.

Authors:  Eleni Aklillu; Natasa Djordjevic; Juan Antonio Carrillo; Eyasu Makonnen; Leif Bertilsson; Magnus Ingelman-Sundberg
Journal:  OMICS       Date:  2013-12-31

8.  Xanthine oxidase activity is influenced by environmental factors in Ethiopians.

Authors:  Eleni Aklillu; Juan Antonio Carrillo; Eyasu Makonnen; Leif Bertilsson; Magnus Ingelman-Sundberg
Journal:  Eur J Clin Pharmacol       Date:  2003-08-21       Impact factor: 2.953

9.  The pharmacokinetics of codeine and its metabolites in Blacks with sickle cell disease.

Authors:  Stacy S Shord; Larisa H Cavallari; Weihua Gao; Hyun-Young Jeong; Kelly Deyo; Shitalben R Patel; Joseph R Camp; Susan M Labott; Robert E Molokie
Journal:  Eur J Clin Pharmacol       Date:  2009-04-09       Impact factor: 2.953

Review 10.  Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I.

Authors:  Shu-Feng Zhou
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.